Determination of concentration of light chains in serum and urine in patients with multiple myeloma

Izeta Aganović-Mušinović, Lukša Pranjić, Alma Sofo-Hafizović, Sanida Ljaljević

Abstract


Introduction: Multiple Myeloma (MM) is a malignant disease of the hematopoietic system, which is classified as malignant tumor of mature B-lymphocytes according to the classification of WHO. Multiple Myeloma is characterized by an uncontrollable monoclonal proliferation of bone marrow plasma cells. The main goal of this study was to present the importance of determining κ and λ chains in serum and urine, as well as their ratio in patients with Multiple Myeloma according to various stages of disease and to compare them with the control group.

Methods: The research was conducted at the Clinic for Hematology, University Clinical Center Sarajevo (UKCS). The study included 82 patients of both genders (41 male, 41 female). The control group included 20 healthy volunteers, both genders. The conducted research was a clinical, cross-sectional, descriptive study.Methods of work were Immunoelectrophoresis - for determining Bence-Jones proteins in urine. Determining the concentrations of free light chains in patients with Multiple Myeloma was done using the nephelometric method in serum and urine.

Results:Patients with Multiple Myeloma had a statistically significantly higher ratio value of κ/λ chains in serum 3,9 (0,57-22,48) when compared to the control group 1,35 (1,15-1,79) (p=0,025), as well as, significantly higher ratio value of λ chains in urine 0,007 (0,003-0,003) in comparison with the control group 0,0 (0,0-0,0) (p<0,001). Patients with Multiple Myeloma had a statistically significantly higher ratio value of κ/λ chains in urine 18,49 (0,27-73,29) in comparison with the control group  of volunteers 0 (0-0) (p<0.001).

Conclusions: The results of our research have shown that the ratio of κ/λ chains in the serum of patients with MM had a significantly higher value 3,9 (0,57-22,48) in comparison with the κ/λ chains in the serum of the control group of volunteers 1,35 (1,15-1,79) (p=0,025).

Key words: Multiple Myeloma, light chains, heavy chains, Immunoelectrophoresis


Full Text:

PDF

References


Elias Campo, Steven H. Swerdlow, Nancy L. Harris, Stefano Pileri, Harald Stein, and Elaine S. Jaffe.The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood. 2011; 117(19): 5019–5032.

Raab MS, Podar K, Breitkreutz I, Richardson PG, Anderson KC. Multiple myeloma.

Lancet. 2009;374(9686):324-39.

Macauda A, Calvetti D, Maccari G, Hemminki K, Försti A, Goldschmidt Het al. Identification of miRSNPs associated with the risk of multiple myeloma. Int J Cancer. 2016; 15;139(8):1703-14.

Joan Bladé, Laura Rosiñol, Carlos Fernández de Larrea. How I treat relapsed myeloma. Blood 2015; 125:1532-1540

Ramón Vélez, Ingemar Turesson, Ola Landgren, Sigurdur Y Kristinsson and Jack Cuzick Incidence of multiple myeloma in Great Britain, Sweden, and Malmö, Sweden: the impact of differences in case ascertainment on observed incidence trends. BMJ Open. 2016; 6(1): e009584.

Riedel DA, Pottern LM. The epidemiology of multiple myeloma. Hematol Oncol Clin North Am. 1992; 6(2):225-47.

Perrotta C, Staines A, Codd M et al. Multiple Myeloma and lifetime occupation:

results from the EPILYMPH study. Journal of Occupational Medicine and Toxicology

;7:25

Abraham S.R., Clark J.R, Bryant C.S., Lymp F.S., Larson T., Kyle A.R. et al. Correlation of Serum Immunoglobulin Free Light Chain Quantification with Urinary Bence Jones protein in Light Chain Myeloma. Clinical Chemistry 2002; 45 (4): 655-657.

Anderson KC, Carrasco RD. Pathogenesis of Myeloma. Annu. Rev, Pathol. Mech.

Dis. 2011;6:249-74

Mateos MV, Landgren O. MGUS and Smoldering Multiple Myeloma: Diagnosis and Epidemiology. Cancer Treat Res. 2016;169:3-12.

International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003;121(5):749-57.

Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. ancer. 1975;36(3):842-54

Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Bladé J i sur. International staging system for multiple myeloma. J Clin Oncol. 2005; 20;23(15):3412-20.

Hutchison CA, Plant T, Drayson M, Cockwell P, Kountouri M, Basnayake K, Harding S, Bradwell AR, Mead G. Serum free light chain measurement aids the diagnosis of myeloma in patients with severe renal failure. BMC Nephrol. 2008; 22:9-11.

Drayson M, Tang LX, Drew R, Mead GP, Carr-Smith H, Bradwell AR. Serum free light-chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma. Blood. 2001;97(9):2900-2.

Katzmann JA, Dispenzieri A, Kyle RA, Snyder MR, Plevak MF, Larson DR, Abraham RS, Lust JA, Melton LJ 3rd, Rajkumar SV. Elimination of the need for urine studies in the screening algorithm for monoclonal gammopathies by using serum immunofixation and free light chain assays. Mayo Clin Proc. 2006;81(12):1575-8.

Katzmann JA, Abraham RS, Dispenzieri A, Lust JA, Kyle RA. Diagnostic performance of quantitative kappa and lambda free light chain assays in clinical practice. Clin Chem. 2005; 51(5):878-81.

Kang SY, Suh JT, Lee HJ, Yoon HJ, Lee WI. Clinical usefulness of free light chain concentration as a tumor marker in multiple myeloma. Ann Hematol. 2005;84(9):588-93

Song P, An ZM, Zhou XG, Li F, Wang LP, Zhao Q, Yu YP, Zhai YP. [Test of Serum Free Light Chain and Its Clinical Significance in Light Chain Multiple Myeloma]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2015;23(5):1357-61.

Mead GP, Carr-Smith HD, Drayson MT, Morgan GJ, Child JA, Bradwell AR. Serum free light chains for monitoring multiple myeloma. Br J Haematol. 2004;126(3):348-54.

Malysz J, Zhu J., Creer MH, Dolloff NG, Bayerl MG, Talamo G. Retrospective study of quantitative free light chain levels in random urine of patients with multiple myeloma. Journal of HematologicalMalignancies, 2013; 3(2): 8-15.

Yang JJ, Zhang GS, Chen XR. [Analysis of monoclonal protein in 72 cases of multiple myeloma]. Hunan Yi Ke Da Xue Xue Bao. 2001; 26(2):152-4.

Herkner KR, Salzer H, Böck A, Mühl A, Tsaka T, Steger H, Pollak A, Schatten C, Popp W, Huber-Spitzy V, et al. Pediatric and perinatal reference intervals for immunoglobulin light chains kappa and lambda. Clin Chem. 1992; 38(4):548-50.

Bradwell AR Hevylite: Concepts. 6th International Symposium of Clinical Applications of Serum Free Light Cahin Analysis (plus Hevylite), Bath, UK, 2010.

Kyrtsonis MC, Vassilakopoulos TP, Kafasi N, Sachanas S, Tzenou T, Papadogiannis A, Galanis Z, Kalpadakis C, Dimou M, Kyriakou E, Angelopoulou MK, Dimopoulou MN, Siakantaris MP, Dimitriadou EM, Kokoris SI, Panayiotidis P, Pangalis GA. Prognostic value of serum free light chain ratio at diagnosis in multiple myeloma.Br J Haematol. 2007;137(3):240-3.


Refbacks

  • There are currently no refbacks.